La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Mega Lifesciences Gestion

Gestion contrôle des critères 2/4

Le PDG Mega Lifesciences' est Vivek Dhawan, nommé en Jan1988, a un mandat de 36.58 ans. détient directement 6.62% des actions de la société, d'une valeur de THB 2.24B. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 26.6 ans et 11.5 ans.

Informations clés

Vivek Dhawan

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	36.6yrs
Propriété du PDG	6.6%
Durée moyenne d'occupation des postes de direction	26.6yrs
Durée moyenne du mandat des membres du conseil d'administration	11.5yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Vivek Dhawan (63 yo)

36.6yrs

Titularisation

Mr. Vivek Dhawan has been the Chief Executive Officer of Mega Lifesciences Public Company Limited since 1988 and has been its Chief Coach since 2013. Mr. Dhawan started with Medicap and built Lupin Laborat...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Vivek Dhawan	CEO, Chief Coach & Executive Director	36.6yrs	pas de données	6.62% THB 2.2b
Thomas Abraham	CFO & Executive Director	26.6yrs	pas de données	0.76% THB 251.7m
Deepak Panjwani	Chief Risk & Compliance Officer	no data	pas de données	pas de données
Paramjit Sawhney	President of International	no data	pas de données	1.5% THB 494.0m
Girish Wadhwa	President of Myanmar	no data	pas de données	pas de données
Manoj Gurbuxani	Deputy Chief Financial Officer	4.6yrs	pas de données	0.000010% THB 3.3k
Duangnapa Tongsiri	President of Mega We Care Thailand	no data	pas de données	1.48% THB 486.3m
Sujintana Boonworapat	Corporate Secretary	no data	pas de données	0.021% THB 6.8m

26.6yrs

Durée moyenne de l'emploi

57.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de MEGA est chevronnée et expérimentée (ancienneté moyenne 26.6 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Vivek Dhawan	CEO, Chief Coach & Executive Director	11.6yrs	pas de données	6.62% THB 2.2b
Thomas Abraham	CFO & Executive Director	26.6yrs	pas de données	0.76% THB 251.7m
Yim Chi	Independent Vice Chairma	11.5yrs	฿1.58m	pas de données
Kirit Chimanlal Shah	Non-Executive Director	11.5yrs	฿661.50k	50.13% THB 16.5b
Shiraz Poonevala	Non-Executive Director	11.5yrs	฿661.50k	pas de données
Ishaan Shah	Non-Executive Director	11.5yrs	฿661.50k	pas de données
Mechai Viravaidya	Independent Chairman	11.5yrs	฿2.21m	pas de données
Sameera Shah	Non-Executive Director	11.5yrs	฿661.50k	pas de données
Thor Santhisiri	Independent Director	11.5yrs	฿1.15m	0.013% THB 4.2m
Vijay Karwal	Independent Director	3.3yrs	฿1.15m	pas de données
Nithinart Sinthudeacha	Independent Director	1.6yrs	฿1.15m	pas de données

11.5yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration MEGA sont chevronnés et expérimentés (durée moyenne d'administration 11.5 ans).

Mega Lifesciences Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Less than half of directors are independent

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Recent updates

First half dividend of ฿0.80 announced

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

PDG

Titularisation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen